Posted on 02/06/2009 in Pharmaceutical Company Product News Novo Nordisk has discussed the problems some patients face as a result of insulin administration.
Dr Christoph Koenen is the corporate vice-president of the company's global medical affairs division and noted there can often be a fear of weight gain and hypoglycaemia when taking this treatment.
Now a study of the firm's Levemir against insulin glargine has shown the drug to have some benefits for those with type 2 diabetes.
It is the first investigation of its kind, pointed out Dr Koenen, adding the treatment was found to provide 24-hour action and resulted in the patient putting on less weight.
He stated there is now another therapy option, which will be important to both physicians and sufferers.
"By allowing patients to take control of their dosing to reach HbA1c targets, better compliance can be achieved," stated Dr Koenen.
"The ? study shows that once-daily Levemir allows patients to do this and maintain optimal control over their condition."
Last week, results published in Expert Opinion Pharmacotherapy showed Novo Nordisk's prefilled insulin delivery device ? the Generation FlexPen ? has a lower injection force than the SoloStar and the KwikPen.Other news stories from 02/06/2009
Read more in the Zenopa News Archive
How this news is generated
|
